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Abstract
Bessac, Bret F., M.S. May, 1998 Pharmaceutical Sciences
Title: Depression-like Behavioral and Endocrine Effects of Brain
Glucocorticoid Type I Receptors In the Male Rat
Advisor: Craig A. Johnston, Ph. D .^
Much evidence ties decreased brain glucocorticoid receptors together with 
anxiety and clinical depression. There are two known types of glucocorticoid 
receptors in the brain, type I (MR) and type II (GR). MR and GR often coexist in 
hippocampal and other limbic neurons and often cause different effects within 
these neurons, within the brain and in animal behavior. The present study 
examined the effects of chronic alterations in the stimulation of brain MR on 
depression associated behaviors using an open field test, circadian and 24-hour 
locomotor activity and plasma corticosterone (B). Rats were chronically exposed 
to an intracerebroventricular infusion of vehicle (propylene glycol), MR agonist 
(aldosterone) or MR antagonist (spironolactone) using ALZET mini-osmotic 
pumps. Two days following pump placement locomotor activity was monitored for 
24 hours in all rats. Spironolactone decreased in total 24-hour activity from pre­
treatment control levels and all other treatments, (p<0.01). This effect was most 
pronounced during the dark phase of the light cycle. There was no difference 
between any of the treatment groups in plasma B concentration determined by 
RIA, nor inner nor outer squares entered in the open field test. Intracerebral 
infusions decreased open field activity, although this was not correlated with the 
treatment. MR were examined using a monoclonal antibody raised to the renal 
MR ligand-binding domain and GR were examined using a polyclonal antibody. 
GR were observed in both kidney and hippocampal tissues, MR were observed 
only in the kidney. This was true for both immunocytochemical and Western blot 
analysis.
The results provide evidence that brain MR are linked to locomotor activity, and 
potentially depression. Furthermore, evidence was collected to suggest that 
hippocampal MR are different from renal MR.
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Chapter 1 
Introduction
Almost everyone suffers from depression sometime during their life. 
Some people feel this emotional state at an extreme level for a prolonged period 
of time, and to such an extent, that they are unable to carry on a normal and 
productive life. In the Diagnostic and statistical manual of mental disorders (4th 
Edition), the American Psychiatric Association has defined a major depression 
episode in an adult as having four or more of the following criteria for most of 
every day for at least two weeks, in addition to having a depressed mood or loss 
of pleasure or loss of interest: 1) a change in weight or appetite, 2) a change in 
sleep, 3) psychomotor agitation, 4) decreased energy, 5) feelings of 
worthlessness or excessive guilt, 6) difficulty thinking or concentrating or making 
decisions, and 7) recurrent thoughts of death, suicidal ideation, or attempted 
suicide.^
Major depression is often associated with an environmental stressor, such 
as a death of a loved one, loss of employment, etc. Endogenous stressors and 
several diseases with endocrine malfunctions or changes are often associated 
with depression. These include diabetes mellitus, Cushing's disease, excessive 
glucocorticoid therapy, hypothyroidism, post-partum depression, menopause, 
pre-menstrual syndrome, and oral and subcutaneous contraceptive therapy,
1
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decrease in exposure to sunlight (seasonal affective disorder) /  56789 10
Depression demonstrates an age and gender-related association. To 
examine whether gender differences or any particular age group in the 
population suffers a greater incidence of depression, or more precisely, has a 
greater incidence of prescribed anti-depressant therapy, a survey of population 
eligible for Montana MedicAid in 1995 was performed. The MedicAid data base 
allowed for gender and age demographics of the recipients of antidepressants.
Many neurochemical theories for the etiological basis for depression have 
been proposed. However most of these have serious problems in time from 
when therapy was first applied, time when neurochemical changes occur, and 
time when patient notices a therapeutic benefit. Medical research of the 
pharmacology of antidepressant drugs, physiological parameters of patients with 
depression, physiological and behavioral parameters in animal models of 
depression and the shared characteristics of endocrine stressors associated 
with depression has provided evidence that a chronic decrease in available 
brain glucocorticoid type I (MR) or type II receptors (GR), or both, could be 
involved in the etiology of depression.
In 1967. Seligman et. al., suggested an animal model for modeling human 
depression known as the learned helplessness model. The methodology of 
this model is to chronically expose an animal to a stressor which this animal 
cannot escape. Eventually the animal quits attempting to escape the stressor, 
even when this animal is provided with a method of escape from the stressor,
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the animal is incapable of attempting such an escape, while an untreated animal 
readily performs the escape/^ Seligman and others have adapted these results 
to clinical psychological therapy, such as learned optimism, providing 
environments and methods for people to have self-control of stressors and 
reinterpretation of uncontrollable stressors/^
Learned helplessness animals, as well as depressed humans, have been 
shown to exhibit abnormal function of the hypothalamic-pituitary-adrenal (HPA) 
axis. The HPA axis is the primary pathway by which the brain regulates the 
secretion of the adrenal glucocorticoids, corticosterone or cortisol (CORT). The 
paraventricular nucleus of the hypothalamus (PVN) synthesizes many 
neuropeptides, including corticotrophin-releasing hormone (CRH) and arginine 
vasopressin (AVP). These peptides are transported down neuronal axons and 
secreted from terminals in the median eminence into the blood of the 
hypophyseal portal blood vessels. These vessels carry blood directly from the 
median eminence to the anterior pituitary, where the CRH and AVP bind to their 
respective receptors on corticotroph cells of the anterior pituitary. The binding of 
CRH and AVP to their membrane G-protein receptors induces the corticotrophs 
to secrete the hormonal peptide, adrenocorticotropin (ACTH), into the blood. 
ACTH travels in the blood from the anterior pituitary to the adrenal gland located 
at the top of the kidney, where it binds to ACTH receptors found in the adrenal 
cortex and medulla. Here, it stimulates the adrenal gland cells to synthesize and
4
secrete steroid hormones including CORT from the cortex and stimulates the 
synthesis of catecholamines within the adrenal medulla/^
CORT (cortisol in humans and corticosterone in rats) is relatively 
insoluble in the blood, and so, travels through the blood primarily bound to a 
carrier protein, cortisol binding globulin. However, CORT is soluble in the 
cellular non-polar lipid bilayer of the plasma membrane, and thus readily enters 
into the cytosol of the cells. Certain cells express one or two of the known types 
of receptors for CORT, MR and GR. Both GR and MR share the protein motif of 
the steroid receptor superfamily, which includes estrogen, retinoic acid, etc.^  ̂
The receptors in this family bind steroids in the cytosol prompting the steroid- 
receptor complexes to transfer into the cell nucleus where they bind directly to 
specific sequences of DMA. The steroid-receptor complex binding onto these 
DMA response elements can directly affect mRNA transcription, and thereby 
affecting protein synthesis.
GR are found thoughout the body and thought to be primarily responsible 
for the plethora of actions of CORT in the mammalian body including anti­
inflammatory, immunosuppressive, metabolic and tubular functions, as well as 
effects on glomerular filtration, muscle catabolism, bone structure, and actions 
on many CNS nuclei. In the brain, GR have been found with highest densities 
in cortex layers (II, III & VI), amygdala (central & posterolateral), hippocampus 
(CA1, CA2, stratum pyramidalis, dentate gyrus & subfonical organ), bed nucleus 
of the stria terminalis (medial, lateral & septohypothalamic), hypothalamus
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(parvocelluar cells of the paraventricular, medial preoptic, periventricular, 
dorsomedial and arcuate nuclei; as well as the tuber cinereum), thalamus 
(laterodorsal), lateral geniculate, Edinger-Westphal nucleus, dorsal raphe 
nucleus and locus coeruleus/^
Brain MR have been found to bind CORT with a much higher affinity than 
peripheral MR. In the brain, the MR are found predominantly in the hippocampal 
formation with much lesser concentrations in lateral septum, amygdaloid bodies, 
olfactory nucleus, cortex layer II, cerebellum and brain stem.^® The rest of the 
brain appears to be relatively devoid of MR. Rat brain MR receptor mRNA are 
thought to be identical to the MR mRNA found in the kidney, where aldosterone 
and other mineralocorticoids act to increase kidney sodium reabsorption. 
Kidney MR bind mineralocorticoids. such as aldosterone and deoxy­
corticosterone, but not CORT, because the MR have a different ligand binding- 
site than GR and are co-localized with the enzyme 11-beta hydroxysteroid 
dehydrogenase II (HSD-II).^ HSD-II oxidizes the 11-carbon hydroxyl of CORT. 
In physiological conditions, aldosterone forms a hemi-acetyl between the 18- 
aldehyde and the 11-hydroxyl, which protects the 11-hydroxyl substituent. 
Deoxycorticosterone does not have an 11-hydroxyl. Therefore, these molecules 
maintain binding ability.^^
There has been no evidence of HSD-II in the brain. Therefore brain MR  
do bind CORT.^^ In fact, these brain MR have a 10-fold higher affinity for CORT 
than do the GR of the brain.^® The identical DNA of the kidney and hippocampal
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MR implies the proteins are identical. However, the large difference in CORT 
binding in these two tissues (no binding in the kidney and high affinity binding in 
the hippocampus) suggests that the proteins comprising the ligand-binding site 
are different. Splice variants of MR have been identified in the hippocampus 
and post-translation modifications are possible. To test whether the
binding site of both tissue MR are identical a monoclonal antibody specific to the 
rat kidney ligand binding site was tested in the kidney and hippocampus by 
immunohistochemistry and Western blot.
CORT is secreted in a circadian manner, with a peak in humans in early 
morning and a nadir late at night. It is also secreted in response to stressful 
stimuli and 24-hour CORT levels rise in response to chronic immunological or 
environmental stress. Brain MR are thought to be always at least 80% bound by 
CORT. However, the amount of CORT bound to GR is thought to fluctuate 
between 5% to 90% bound during a 24 hour day, depending on the CORT 
available.
In order to regulate CORT secretion, CORT receptors directly or indirectly 
decrease CORT synthesis, as well as the synthesis and secretion of the 
hormonal peptides of the HPA axis. GR are thought to be primarily involved in 
mediating the feedback inhibition on the HPA axis peptides (ACTH and CRH).^  
27 28 29 activation inhibits the expression of CRH mRNA In the PVN and in 
the pituitary pro-opiomelanocortin (POMC) peptide mRNA (the pro-peptide of 
ACTH).^^ MR in the hippocampus are also thought to be involved with regulating
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the amount of CORT secreted and the basal circadian rhythm of CORT  
secretion, although the neurological or biochemical mechanisms underlying this 
are not yet understood.^° Decreases of MR or blocking MR binding in the 
hippocampus, and decreases of GR or blocking GR binding in the hypothalamus 
(but not GR in the hippocampus) are positively correlated with an increased 
activation of the HPA axis, resulting in increased plasma CORT.^^
Patients with diseases which are associated with chronic alterations in 
CORT secretion often exhibit symptoms seen in depression.^ These diseases 
include Cushing's disease, Addison's disease, diabetes mellitus, autoimmune 
disorders, multiple sclerosis, and exogenous therapy with CORT analogs. In 
animals, many of these diseases are associated with a decrease in GR and MR 
levels.^ ^  In animal models with an altered HPA axis activity by disease or 
pharmaceuticals, there is often a presence of behaviors associated with human 
depression and animal learned helplessness, such as diminished response to a 
stressor, feeding, cognitive behavior, adaptive behavior, decreased explorative 
behavior and decreased 24-hour locomotor activity.^®
In many people with depression, and in learned helplessness animals, the 
peaks and valleys of CORT circadian rhythm are diminished and there is an 
overall increase in total daily plasma CORT levels.^  ̂ Also, learned helplessness 
animals and depressed people often have a less of decrease in plasma cortisol 
or pituitary ACTH in response to dexamethasone (a synthetic glucocorticoid) 
administration.  ̂ ^  This diagnostic test is known as the dexamethasone
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suppression test. In one study, non-suppression of plasma cortisol level by 
dexamethasone was noticed in 72% of patients with major depression; 87% of 
those with melancholia, 100% of mixed bipolars, but only 33% of those with 
mania only.^^
The inability of dexamethasone to decrease plasma CORT and ACTH 
levels and the abnormal CORT circadian rhythm in people with depression 
implies the CORT receptors in the brain, pituitary and/or adrenal glands (adrenal 
CORT synthesis is regulated by GR) are low or less responsive. Both brain GR 
and MR are reduced with chronic immobilization and similar chronic stress 
(models of learned helplessness).^® ®̂
Dexamethasone non-suppression, loss of CORT circadian rhythm with 
chronic CORT hypersecretion, and depressed mood often normalizes after 
about ten to fourteen days of antidepressant drug therapy, even though 
neurochemical changes occur within minutes to hours. Historically, 
antidepressant drugs were derived from plants, such as Hypericum perforatum 
(St. John's Wort) and Erthroxylan Coca sp. (cocaine). In the early 1950's, 
investigations by Zeller, by Crane and by Kline noticed alleviation of depression 
with a synthetic drug originally used for treating tuberculosis, isoniazid. In the 
late 1940's, Haeflinger and Schindler synthesized imipramine, which Kuhn 
characterized in 1958 as having antidepressant actions. Imipramine led to the 
synthesis of other similar molecular tricyclic antidepressant drugs (TCAs). In 
order to remove many of the side effects of TCAs, chemical blockers of the
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presynaptic neuronal reuptake transport systems of serotonin (SSRI) have been 
synthesized and used successfully to treat depression.
Antidepressants are not the only biological manipulators successful in 
depression treatment. Electroconvulsive shock therapy (ECT) has been used as 
a treatment for the immediate resolution of depression. In seasonal affective 
disorder, exposure to intense UV light for about an hour per day is an effective 
therapy. Lithium has been successfully prescribed for bipolar disorder.
Isoniazid and extracts of St. John’s Wort inhibit the enzyme monoamine 
oxidase (MAO).^"* MAO oxidizes the amine on serotonin and catecholamines, 
thereby making these molecules inactive at their receptors. Inhibitors of MAO 
allow serotonin, dopamine and norepinephrine to remain active in the neuronal 
synaptic cleft for a greater time and concentration. The antidepressant TCAs 
and cocaine competitively inhibited the neuronal reuptake transport systems for 
serotonin and/or catecholamines. Competitive inhibition refers to the fact that 
the drugs directly block the site were catecholamines or serotonin interact. 
SSRIs are designed to only inhibit the reuptake of serotonin. Neuronal reuptake 
transporters act physiologically to remove neurotransmitters from the neuronal 
synaptic cleft by transporting them back into the pre-synaptic neuron. Similar to 
MAO, reuptake inhibitors increase the time and concentration of catecholamines 
and/or serotonin in the synaptic cleft. All of these drugs result in an increase of 
catecholamines and/or serotonin in the neuronal synapse within minutes of 
intake. However, the maximal therapeutic antidepressant benefits are not
10
noticed for about 10-14 days, which confounds theories suggesting that only low 
synaptic serotonin and/or catecholamines are directly responsible for the onset 
of depression.
Drugs which reduce serotonin secretion or synthesis and/or 
catacholamine secretion or synthesis, such as reserpine, 3 ,4 -methylenedioxy- 
methamphetamine, 5,7-dihydroxytryptamine, p-chloroamphetamine, or 6 - 
hydroxy-dopamine all decrease hippocampal GR and MR.®® s? se 59 so ei S2 
Serotonin within the hippocampus acts to increase GR and MR expression. Both 
hippocampal MR and GR levels increase after chronic treatment with SSRIs, 
TCAs, MAO inhibitors, lithium, or following ECT in a time course which is similar 
to the observed effect of these therapies on human mood.®® ®̂ ®® ®® ®̂ ®® ®® 
These results coupled with HPA axis anomalies of patients with depression 
directed our attention toward GR and MR in the etiology of depression.
Acute administration of pharmacological GR antagonists have induced 
depression-like animal behaviors.^^ ^  ^  Chronic low GR have been
demonstrated in mice with depression-like behaviors and endocrine parameters. 
Antidepressants attenuate the HPA axis hypersecretion and depression-like 
behaviors in a mouse model expressing GR mRNA anti-sense.^® The 
characteristics of these mice, including hypersecretion of the HPA axis, 
dexamethasone non-suppression and learned helplessness-like behaviors,
provide evidence that depression may involve a decrease in brain GR levels.^
79 80 81 82
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To directly examine the consequences that a chronic decrease in 
available brain MR would have on the HPA axis and depression-like behaviors, 
an animal model of chronic low MR has been explored.^ An 18-base end anti­
sense to MR was delivered into the third cerebral ventricle of a rat with an 
osmotic mini-pump for 7 days. Changes were examined in hippocampal GR, 
MR, MR mRNA, a stress behavioral test, morning (nadir) plasma ACTH and 
CORT, and plasma ACTH and CORT after the behavioral test stressor. MR anti­
sense treatment did not affect hippocampal GR levels, morning plasma ACTH or 
CORT concentrations nor anxiety-like behavior from the stress test (social 
defeat and then an elevated plus-maze). As would be expected, hippocampal 
MR levels decreased (21%) and MR mRNA increased from the treatment. There 
was a slight but significant increase of plasma ACTH, but not CORT, in response 
to the behavioral test in the treated rats.
The MR antisense treatment only produced a 21% decline in hippocampal 
MR concentrations. In the present experiments, a similar model was examined 
but using continuous administration of a MR antagonist, which theoretically 
would provide a greater decrease in the available hippocampal MR. In this 
model six days of constant administration of the MR antagonist, spironolactone, 
directly into a cerebral ventricle of a rat by an osmotic mini-pump was used. 
Chronic administration of a MR antagonist given centrally should increase basal 
plasma CORT concentration. Plasma CORT, 24-hour locomotor activity (to
12
monitor circadian rhythm), and open field tests (a behavioral test of anxiety) 
were all measured in this model.
In another experiment the chronic administration of a MR agonist, 
aldosterone was utilized, to determine the effects of chronic MR activation on the 
same parameters. An agonist is a drug which binds to the receptor and elicits 
the receptor to respond in a manner similar to the endogenous ligand, in this 
case the agonist-steroid receptor complex binding onto DNA. Unlike CORT, 
neither aldosterone (nor spironolactone) have a high affinity for GR.^  ̂ Chronic 
administration of a MR specific agonist given centrally should decrease basal 
CORT and blunt CORT circadian peak levels. Since MR are always about 80% 
bound, increasing the amount of available ligand may not produce noticeable 
behavioral/neurochemical effects.
Changes in weight, dexamethasone non-suppression, loss of CORT  
circadian rhythm and high 24-hour CORT in people with depression, and the 
higher incidence of depression in people having diseases or hormonal therapies 
which are associated with abnormal CORT levels implies that CORT and it's 
receptors may be involved in the etiology of depression. The loss of normal 
CORT circadian rhythm, dexamethasone non-suppression, decreased 
hippocampal MR and GR in animal models of learned helplessness, the anxiety 
and depression-like behaviors of animals demonstrating decreased brain GR 
and the increased animal hippocampal MR and GR seen in animals tested with 
TCAs, SSRIs, lithium or ECT in a time course similar to their therapeutic effect,
13
provide further evidence that chronic decreases in hippocampal GR is involved 
in the etiology of depression. The present experiments examined the behavioral 
and hormonal effects of chronic alterations in central MR binding and MR’s 
possible role in the etiology of depression.
C hapter 2
M aterials and M ethods
Procedure
Acclimate to cages
-4 Day: 24hr Cage activity
-3 Day: Open field activity
-2 Day: Intra-jugular cannula- leftside
-1 Day: Pre-Treatment Plasma samples at 8:00, 14:00, 18:00
0 Day: Set up osmotic pumps
1 Day: Insert brain cannulae and osmotic pumps
2 Day: Rest from surgery
3 Day: 24hr Cage activity
4 Day: Open field activity/ Intra-Jugular cannula- rightslde
5 Day: Treatment Plasma samples at 8:00, 14:00, 18:00
20:00 PBS perfusion; remove brains; cannula patency assessed
Animals
Forty 250g-300g adult male Spague-Dawley rats were obtained from 
Harlan Labs. They were housed singly in the Pharmacy/Psychology Vivarium, 
an AAALAC accredited facility, with rat chow pellets and water ac/ libitum, in 
standard environmental conditions (white light on 7:00-19:00 and 23°C +/- 1°C). 
Rats were housed and maintained according to guidelines published in NIH 
Principles for Use of Animals. Guide for Care and Use of Laboratorv Animals.^
14
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Materials
Rat chow (Purina), Micro-osmotic pumps and brain infusion kit (Alzet 
1007D, Alza, Palo Alto, CA), sodium laurel sulfate, d-aldosterone, 
spironolactone, glycine, diaminobenzene, triton-X 100, para formaldehyde, 
xylene, peroxidase conjugated rabbit anti-mouse and anti-rabbit antibodies 
(Sigma, St. Louis, MO), Tween-20, TRIS base, propylene glycol, sodium 
hydroxide pellets (J.T.Baker, Phillipsburg, NJ), #0-80 x 1/8" screws and #56 drill 
bits (Small Parts, Miami Lakes, FL), dental cement Fastray powder and liquid 
(Harry J. Bosworth, Inc., Stokie, IL), 2,2,2-tribromoethanol (TBE) (Fluka, 
Ronkonkoma, NY), silicone plastic (Silastic) tubing and non-reinforced silicone 
plastic sheeting 0.25 x 3.25 x 0.03 in. (Konigsberg Instruments, Inc., Pasadena, 
CA), 100% silicone aquarium sealant (Dow Corning Corp., Dayton, OH), 
cardiovascular 4-0 silk (Ethicon, Inc., Somerville, N. J.), wound clips, 23G1 
needles, polyethylene tubing PE50, microscope slides and 5cc, 3cc and Icc  
syringes (Becton Dickinson, Inc., Parsippany, NJ), heparin sodium, sodium 
phosphate monobasic, sodium phosphate dibasic, 30% hydrogen peroxide, 
microscope cover glass (Fisher, Fair Lawn, NJ), sodium chloride (EM Industries, 
Inc., Gibbstown, NJ), T^^corticosterone radioimmunoassay kit (Amersham Life 
Science Inc., Arlington Heights, IL), Glucocorticoid receptor II and 
mineralocorticoid receptor mouse monoclonal antibodies (Affinity BioReagents, 
Golden, CO), biotinylated anti-rabbit antibody. Reagent A and Reagent B 
(Vector Laboratories, Burlingame, CA), DPX mountant for microscopy (BDH
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Laboratory Supplies, Poole, England, UK), 8 x 10 wells WHO trays, 5.25%  
sodium hypochlorite (Shurfine, Northlake, IL), 10% CAP gel TRIS SDS 8x10cm 
(ION Biomedicals, Aurora. OH), 15 gauge trochar (Innovative Research, 
Rockville, MD), immobllon-P transfer membranes (Millipore, Bedford, MA) were 
purchased commercially. Reagent A and B (Transduction Laboratories, 
Lexington, KY) was a gift from Dr. Charles Eyer. Biotinylated anti-mouse 
antibody (Vector Laboratories, Burlingame, CA) was a gift from Dr. Diana Lurie. 
Protein Assay Dye (Bio-Rad, Hercules,CA) was a gift from Dr. Keith Parker. 
Film developer (GBX) and fixative reagents were gifts from Dr. Michael Mlnnlck.
Apparatuses
Stereotaxic apparatus (Kopf, Tunga, CA), a cryostat (HistoStat, Reichert- 
Jung, Buffalo, NY), drill (Model 750, Dremel, Racine, Wl), submini lever switches 
(Radio Shack, Fort Worth, TX), 386 computers (Dell), pipetmans (Gilson, 
France), a gamma counter (ICN MIcromedIc Systems, Huntsville, AL), a 
centrifuge (J-68, Beckman, Redmond, WA), a -80®C refrigerator (Environmental 
Equipment, Cincinnati, OH), a camera (Nikon, Japan), Spectrometer (Bausch & 
Laumb), a microscope (Nikon, Japan), homogenizer (Tissue Tearor), 
electrophoresis power supply (ISCO, Lincoln, NE), an electrophoresis transphor 
tank, and an electrophoresis gel tank (Hoefer, San Francisco, CA) were used.
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Methods
Intracerebroventricular Cannulation and Pump Implantation:
Surgeries were conducted with the rats under tribromoethanol (TBE) 
anesthesia (1ml of a 2.5% solution in saline/ kg body weight). The methods 
were similar to those suggested by Alza.^^ The scalp was shaved and washed 
with betadine solution. The animal was then placed in a stereotaxic device (SD), 
a 2.5 cm long incision was made to expose the cranium, a periosteal elevator 
scraped tissue from the skull. Blunt-nose scissors were used to make a 
subcutaneous tunnel from the scalp incision to the mid-scapular area. At the 
end of the tunnel a pocket was made large enough to house the pump and 
permit some pump movement. Two holes were drilled through the skull (one -4 
mm posterior (AP) from Bregma, -2mm lateral from midline and one +2 mm AP, 
+2 mm lateral). Into these holes small stainless steel screws were placed. The 
elevator arm of the SD was altered, so that the end not connected to the SD was 
attached to an alligator clip. The placement tab of the brain cannula was clipped 
and held in place with the alligator clips. The cannula was connected and glued 
with epoxy to 7 cm of catheter tubing (0.69 ID) with 28G needle/syringe filled 
with solution at the other end of tubing. The brain cannula was filled with 
solution. At -1.3 mm AP, a hole was drilled through the skull and the brain 
infusion L-shaped cannula was lowered -4.5 mm from dura into the third 
ventricle.^^ A bolus of 50 pi was injected into the brain to flush any tissue which 
could form a clog and to insure the cannula was patent. The cannula was affixed
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to the skull using dental cement. Once the cement hardened, the tubing on the 
osmotic pump was removed and the pump was attached to the catheter tubing of 
the brain cannula. Then the osmotic pump was inserted into the subcutaneous 
pocket. The placement tab was cut from the top of the cannula and the scalp 
wound closed with small wound clips.
Osmotic Pump:
The Alzet mini-osmotic pumps provided the animals with chronic exposure 
for seven days to intracerebroventriclular (icv) administration of one of three 
treatments: MR antagonist (0.6 mg spironolactone/ 1 ml propylene glycol), MR 
agonist (0.05 mg aldosterone/1 ml propylene glycol) or propylene glycol vehicle. 
The pumps had a mean pumping rate of 1 pl/hour. Therefore, the drug solution 
infusion rates were 600 ng spironolactone/hour or 50 ng aldosterone/hour. The 
solutions were carefully injected through the 25-gauge fill tube and into the 
osmotic pump. The clear plastic top of the universal flow moderator was 
removed. The flow monitor was attached to a 5 mm piece of tubing with a 28- 
gauge needle/syringe filled with solution at the other end of the tubing. Solution 
was pushed into the flow monitor until it was filled with solution. Then the flow 
monitor was carefully inserted into the pump. The pumps were incubated 
overnight in 0.9% saline at room temperature to assure activation of the infusion 
mechanisms.
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Open Field Activity:
Before and four days after surgery, in the late morning (10:00 to 12:00), 
animals were placed In an open field apparatus (an open-top box with 46 cm 
walls and a 122 x 122 cm floor, with a 7.6 x 7.6 cm grid pattern on the floor). A 
video camera recorded the activity In the field for 10 minutes. The time to Initiate 
movement, number of total squares entered and the number of inner squares 
versus peripheral squares (three rows along the walls) entered were assessed. 
Animals were also monitored for rearing, grooming and defecations. The field 
was cleaned with dilute ethanol between each session.
24 Hour Cage Activity:
The apparatuses for locomotor activity measurement were constructed by 
the investigator. Each rat was Individually housed in 42x23 cm opaque plastic 
rat cages covered by two 21 x 23 cm wire cage tops. Each cage top contained a 
similar quanify of water and food, with both the bottles In the middle of the cage. 
Each top, also, held a similar quantity of food. Each cage sat on a fixed round 
rod in such an orientation that the two ends of the cage were balanced, like a 
scale or teeter-totter with the rod being the fulcrum. Under one end of the cage 
was a submini lever switch, so when the rat was on that end of the cage the 
switch was closed, but when the rat moved to the other end of the cage, the 
cage teetered to that side and the switch was opened. The changes of a switch 
from open to closed and from closed to open were quantified for every 15
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minutes for 24 hours through a PC computer interface.®^
Chronic intra-jugular cannula placement:
Prior to surgery, cannulae were made by making a small hole in a 1x2 cm 
silastic sheet at 1/3 of the longer length and the middle of the shorter length, as 
previously described.®^ A piece of 20 cm silastic tubing (0.02 in. ID) was 
threaded through the hole until 5 cm had been threaded through the hole. Then 
silicone glue was dabbed to the 1/3 section of the sheet, this glue covered 
section was folded onto the middle third of the sheet, covering a portion of the 
tubing held tight by binding clips until the glue set. After the glue dried, the 
glued portion of the cannula was trimmed close to the tubing, but the third which 
was not glued remained untrimmed. The portion of the tubing below where the 
sheet was glued to the tubing was cut to a length of 2.8 cm.
Cannulae were surgically implanted under anesthesia of TBE (1 ml/0.1 kg 
BW, of a 2.5% solution in saline) as previously described. The surgical site 
was sterilized with 70% ethanol. An incision was made in the chest to expose 
the pectoral muscle and the jugular vein. The prepared cannula was flushed by 
a syringe filled with heparin (10 kU/ml) attached at the open end with the long 
length of tubing. The other end was attached to an L-shaped 20-gauge/23- 
gauge specially designed needle. ^  The needle was shaped, so that the 
attached cannula and needle were inserted into the Jugular vein just superior to 
the pectoral muscle and then exited the jugular vein beneath the pectoral
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muscle, consequently exiting through the muscle. The needle was removed 
from the cannula and the cannula was pulled back under the muscle and 
carefully guided into the vein. The pressure of the pectoral muscle sealed the 
exit hole. The cannula was threaded through the vein into the right atrium of the 
heart. The untrimmed section of the sheet acted like a tab, which allowed the 
cannula to be anchored to the pectoral muscle by silk thread suture. A 15 gauge 
trochar was pushed subcutaneously from the middle of the back of the neck to 
the wound site. The syringe was removed and the exposed end of the silastic 
cannula was threaded into and through the trochar. The trochar was removed, 
leaving the cannula, which exited the back of the neck. The open end of the 
cannula was cut so that a 5 cm portion was exposed and sealed with a knot 
under pressure with heparinized saline.
Blood Retrieval:
The animals were individually housed in opaque cages with stainless 
steel tops. At least one hour prior to sampling, the knot closing the cannula was 
cut. A 0.75 m PE 50 tube filled with 100 U Heparin/ 1 ml 0.9% saline was 
connected to the cannula by a -5  cm stainless steel tube (28 gauge). The PE 
50 tubing connecting tube was strung to the outside of the cage, where it was 
attached to a another 0.25m piece of PE 50 tubing by "~5 cm stainless steel tube 
(28 gauge). The open end of the 0.25m PE 50 tubing was connected to a 3 cc 
syringe containing at least 1 cc of the heparin/ saline. Plasma samples were
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retrieved by drawing blood up the 75 cm PE 50 tubing and into about a third of 
the 0.25 PE 50 tubing by the 3 cc syringe. The 75 cm and 25 cm PE 50 tubing 
were detached and a 1 cc heparinized syringe with a 28 gauge needle was 
attached to the open end of 0.75m PE 50 tubing and 0.7 ml of blood was slowly 
drawn into the heparinized syringe without disturbing the animal. The two 
pieces of PE 50 tubing were reattached and the blood flushed back into the 
animal with heparin/ saline (100 U/ml). Blood samples were removed at 9:00, 
14:00 and 18:00 hours, before treatment and after 5 days of treatment. Plasma 
was separated by centrifuge at 15,000 rpm and stored at -80**C for hormone 
analysis.
Plasma Corticosterone Radio immunoassay:
Plasma corticosterone (B) was measured using the protocol of the 
corticosterone radioimmunoassay kit.̂  ̂ Plasma samples were placed in a water 
bath at 60^C for 30 minutes to displace B from cortisol binding globulin. One 
hundred microliters of each plasma sample was diluted with 400 fil 0.02M borate 
buffer pH 7.4 with 0.1% sodium azide in a polystyrene tube.
Standards were prepared by pipetting 500 pi of buffer into 18 polystyrene 
tubes. Five hundred microliters of a standard of 400 ng B/ml buffer was pipetted 
into two of the tubes and vortexed. Five hundred microliters of the contents of 
these two tubes was transferred into two other tubes and this double dilution was 
repeated successively with the remaining tubes giving rise to 2 sets of tubes with
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9 different concentrations of B. Aliquots of 100 (xl from each of the serial 
dilutions were pipetted into 2 sets of 9 tubes with respective dillutlons equivalent 
to 0.78, 0.156, 0.312, 0.625, 1.25, 2.5, 5, 10, and 20 ng/ml.
In addition to the labeled standard and sample tubes, 3 tubes were 
labeled TC for total counts, 3 tubes were labeled NSB for non-specific binding, 
and 5 tubes were labeled Bo for zero binding standard. Two hundred microliters 
of buffer was pipetted into the NSB tubes and 0.1 ml of buffer was pipetted into 
the Bo tubes. One hundred microliters of rabbit anti-B (400 ng/ml) was pipetted 
into all tubes except for NSB and TC tubes. One hundred microliters of [̂ ^̂ l]B 
(approximately 11,570 cpm) was pipetted into all of the tubes. Then the TC 
tubes were removed for counting. All other tubes were vortexed, covered and 
incubated for two hours at 22®C. After the incubation, 0.4 ml of the Amerlex-M 
goat anti-rabbit second antibody was pipetted into each tube except TC tubes. 
All tubes except the TC tubes were then centrifuged for 10-20 minutes at 3000 
rpm, 4^C. These tubes’ supernate was aspirated off from leaving a precipitate.
A gamma counter was connected to a computer with Isodata software, a 
protocol was written for a log-logit standard curve; the counts per minute of 
sample binding minus non-specific binding divided by maximum binding (Bo) 
standard minus non-specific binding times 100, versus an X-axis: log dose B 
concentration (ng/ml). The gamma counter read the radioactive counts per 
minute of the standards, NSB, Bo and TC and provided this information to the 
computer, which provided a standard curve. (See Figure 7, page 45) By applying
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this curve to the unknown samples’ counts per minute minus NSB an estimate of 
B concentration in ng/ml could be estimated for each sample. All plasma B was 
measured in the same assay, interassay coeffient of varation=0.02, 50% 
effective dose=2.5 ng B/ml and sensitivity=0.16 ng B/tube
Brain and Kidney Removal:
In order to remove blood cells from brain and kidney samples for western 
blot analysis or immunohistochemical analysis (ICC), the rats were given TBE 
anesthesia and transaortically perfused with 0.1M phosphate buffer saline 
(PBS), pH 7.4 for 5 minutes. Chest hair was scalped off exhibiting subcutaneous 
tissue, an incision was made at the xyphoid process and with a hemostat the 
xyphoid process was pulled through the incision. This separates the peritoneal 
muscle wall from the vital organs, allowing an incision to be made all along the 
diaphragm base of the rib cage. The diaphragm was cut from the ribs, without 
damaging vital organs. Two cuts were made 2-3 inches to the side of, and 
parallel to, the sternum. The hemostat clamped to the xyphoid process was 
pulled to the head of the animal and pericardial tissue was cut from the sternum.
This surgery was performed on a refrigerator rack mounted over a sink. 
Above the sink sat two 10 gallon barrels containing 5% para-formaldehyde 
(RFA) or PBS. A 3 foot piece of 1/4 inch x 1/16 inch class VI plastic tubing was 
attached by an adapter to the spigot of each of the barrels. The tubes were 
connected together by a Y  glass adapter, which had 2 foot tube on the third arm.
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Each tube had a clamp near it’s end. The last tube had a dull-end 13G needle 
attached at the end.
Both the spigots were open and the clamps on the PBS tube and the third 
tube were opened to clear out the tubes with PBS. Then the third tube was 
clamped closed and the needle was inserted into the left cardiac ventricle and 
threaded up the aorta. The third tube was undamped again and PBS flowed 
into the animal. The right cardiac atrium was cut to allow the PBS/blood to exit. 
When the blood had been replaced by PBS. the liver and eyes turned white and 
the exiting fluid became clear. If the tissues were to be analyzed by western 
blot, the needle was then removed. The kidneys and brain were retrieved. The 
cerebral cortex was pealed off and cut from the corpus callosum of the freshly 
retrieved brain. The cerebellum was also removed. The different brain sections 
were then frozen at -80®C.
If the tissues were to be analyzed by ICC. the PFA tube clamp was 
opened and the PBS clamp was closed. PFA flowed into the rat for about 5 min. 
causing the muscles of the rat to constrict and the limbs to curl. The brain and 
kidneys were retrieved and post-fixed in PFA for 4 hours, followed by 
cryoprotection in 30% sucrose in PBS until the tissues sunk (about 2 days).
Immunohistochemistry (ICC) of Brain and Kidney MR and GR:
The cerebellum was removed with a straight-edge razor blade. The 
different brain sections were then frozen at -80°C. A razor blade was used to
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make coronal cuts just caudal to the mamallary bodies and just rostai to the optic 
chiasm. The restai and caudal sections were discarded.
A room temperature cryostatic chuck had tissue freezing medium placed 
on top of it, so that all the indented grooves, except the outer most groove were 
coated with medium. The caudal end of the middle section of frozen brain tissue 
was placed in the freezing medium on top of the chuck. The chuck stem was 
placed in a pre-bore hole rn the dry ice, so that the brain platform sat flat on dry 
ice. The brain dorsal and ventral sides were maintained perpendicular to the 
chuck platform with cold forceps. Once the medium solidified, the chuck/brain 
was placed in the cold (-12*"C) cryostat. The brain was trimmed to the optic 
chiasm (Bregma) using the microtome blade. At about -2.0 mm AP from 
Bregma, the hippocampal folds began to appear. From this point to the 
hippocampal fissure, 40 ^m coronal sections were obtained.
The 40 pm coronal sections were placed in 0.01 M PBS filled W HO tray 
wells with a #2 round artificial horsehair paintbrush. After five minutes, sections 
were moved from one well of PBS to another. Endogenous peroxidase activity 
was removed by immersion of the sections for 10 minutes in hydrogen peroxide 
(500 pi 30% H2 O2 in 30 ml PBS) filled wells followed by two 5 minute washes in 
PBS wells. Sections were blocked with normal goat serum (NGS) in wells filled 
with 200 pi N G S /10 ml DaylB (0.5 g bovine serum albumin/ 50 ml P B S /150 pi 
Triton-X). After one hour, the sections were placed in wells containing rabbit 
polyclonal antibody to GR (Dilution 5pg/ml DaylB) or mouse monoclonal
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antibody to MR in DaylB (Dilution 1:100).®^
Microscope slides were placed in a slide tray. One gram gelatin and 0.5g 
chromic potassium sulfate was dissolved in 1000 ml flask containing 500 ml 
distilled water and gently heated until mostly dissolved. The insoluble gelatin 
was then filtered out. The slides were immersed in a glass tray containing 0.1%  
acid 70% alcohol (290 ml distilled water + 1 ml HCI + 700 ml absolute methanol) 
for two minutes, followed by two minutes in a glass tray with distilled water. The 
slides were then placed for two minutes in gelatin subbing solution and stored 
overnight in an oven at 37°C.
The next day, the sections received two 5 minute washings in wells 
containing Day2B (20 ml DaylB + 40 ml PBS). The sections were then placed in 
wells of biotin conjugated goat anti-rabbit or horse anti-mouse secondary 
antibody in Day2B (Dilution 1:1000). One half hour after the application of 
antibody, a solution to express the biotin made of 50 pi reagent A, 50 pi reagent 
B and 20 ml Day2B (A+B) was made. One hour after immersion in secondary 
antibody, the sections received two 5 minute washings in wells containing 
Day2B, followed by immersion in wells of A+B. One hour after the application of 
A+B, the sections received two 5 minute washings in PBS.
Sections were developed using the chromagen, diamino benzene diluted 
20 mg in 15 ml PBS (DAB+B). The sections were immersed in 1 ml DAB+B + 
19 ml PBS + 6.6 pi 30% H2O2 until sections turn a suntan brown. DAB 
contaminated material other than the sections and the DAB solution were placed
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in 5.25% sodium hypochlorite to destroy the carcinogenic DAB.
The developed sections were placed in a petrl dish filled 3/4 full with PBS 
and mounted onto gelatin coated microscope slides with the paintbrush. The 
slides were air dried, then dehydrated for coverslipping using a series of 
immersions in increasing concentrations of ethanol. First, slides were immersed 
for 5 minutes in 70% ethanol, followed by 5 minutes in 95% ethanol, followed by 
two 5 minute immersions in 100% ethanol and finally two 5 minute immersions in 
xylene. The slides then had DPX mountant applied and a coversiip was secured 
by the DPX. The coverslipped slides dried for 12 hours.
The slides were examined with a Nikon microscope at lOx, 40x and 50x 
powers and photos taken with an attached camera.
SDS Gel Electrophoretic Western ImmunoBlot of Brain and Kidney MR and GR: 
The frozen sections were removed from the refrigerator. A  razor blade 
was used to make coronal cuts just caudal to the mamallary bodies and just 
rostai to the optic chiasm. A room temperature cryostat chuck had tissue 
freezing medium placed on top of it, so that all the indented grooves, except the 
outer most groove were coated with medium. The caudal end of the middle 
section of brain tissue was placed in the freezing medium atop the chuck. The 
chuck stem was placed in a pre-bore hole into dry ice, so that the brain platform 
sat flat on dry ice. Once the medium solidified, the chuck/brain was placed in 
the cryostat. The brain was trimmed to the optic chiasm (Bregma). At about -2.0
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mm AP from Bregma, the hippocampal folds began to appear. A cut was made 
with a razor blade separating the hippocampus and the hypothalamus from this 
point to the end of the section. The hippocampus was stored at -80*'C in pre­
weighed vials on dry ice for Western blot analysis.
The hippocampal and kidney tissues were weighed and 5 ml TRIS buffer/ 
gram tissue sample (200g/l) was added into the vials. The tissues were 
homogenized until completely homogenous to the eye. A Bradford protein 
analysis was conducted on each tissue sample. Samples of 10-300 \xg! well 
were used for Western blot analysis. This amount of protein was pipetted from 
the homogenized sample into an eppendorf tube and q.s. to 40 pi with (6x 
buffer). A pin hole was placed into the top of each tube.
A CAPS pre-poured gel (Amersham) was placed onto the gel 
electrophoretic unit (GEU) with the shorter gel glass plate facing towards the 
electrodes and forming a seal with rubber gasket.^^ The gel plates were clipped 
onto the GEU. A 1 ml glass pipette washed the gel by pouring tank buffer 
(9.075g TRIS, 43.2 g glycine, 3g sodium laurel sulfate in 3L de-ionized water) on 
top of wells. The inner holding area (behind the gel) was loaded with tank buffer 
until level with the top of the shorter glass plates. The seal between the glass 
plate and the gasket was examined for any leaks. If no leaks were observed 
then the lower holding area was filled with tank buffer.
The tissue sample/ 6x buffer tubes were put into a styrofoam float and 
placed in boiling water for 150 seconds. The bottom half of the tubes were
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exposed in the water. Into the first gel well 30 \i\ stained protein standard was 
pipetted with a capillary pipette tip. The rest of the wells had the samples/6x 
pipetted into them.
The electrophoretic power supply had it's parameter's set; meter scale: 
volts, current: 100 mA on 600 V, voltage limit: max., wattage limit: max., current 
limit: 20. The EGU top was connected with the EGU and the power supply. The 
EGU water cooling system and the power supply were turned on.
When the samples' dye had migrated to bottom of the gel, a membrane 
was placed in 100% methanol and the transphor electrophoretic unit (TEU) was 
filled with transphor buffer (20% methanol in tank buffer) to the start fill level, the 
power supply was turned off and the gel was removed. The gel was removed 
from the glass plates and gently placed in transphor buffer. A gel sandwich was 
made in transphor buffer; black side down, sponge, 2 pieces of paper, gel, 
membrane, 2 pieces of paper, sponge, gray side. The sandwich was transferred 
into the TEU with black side facing black electrode end and the TEU was filled to 
minimum buffer level with transphor buffer. The TEU and power supply were 
moved to a cold room and the power supply had it's parameters set; wattage 
limit: max., current limit: max., voltage limit: 20. The TEU was placed on a stir 
plate and a stir bar was spun in the TEU. The power supply was turned on and 
the proteins in the gel transferred into the membrane overnight.®®
The next day, the membrane was removed and air dried. If the stained 
protein standard was noticed on the membrane, the transphor was considered
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successful. The dry membrane was soaked in a blocking solution of (TTBS) with 
5% non-fat milk for an hour. This was followed by placing the membrane in fresh 
TTBS + 5% non-fat milk and a mouse monoclonal M R antibody (Dilution 1:250) 
or a rabbit polyclonal GR antibody (Dilution Ipg /lm l) overnight at 4°C. The next 
day the membrane was washed by soaking it in fresh TTBS every 5 minutes for 
30 minutes, then in TTBS + 5% non-fat milk and horseradish peroxidase 
conjugated secondary anti-body, anti-mouse (1:4000) or anti-rabbit (1:8000) for 
an hour. The membrane was then washed as previously described.
In order to detect and quantify the target protein on a permanent media, 
the membrane was soaked in luminol based chemiluminescent reagents for 2-10 
minutes. Under a red light, the membrane was sandwiched between plastic 
wrap and had electro-chemiluminescent film placed on top of it for 10 seconds to 
5 minutes. The film was developed in GBX developer for 5 minutes, washed for 
a minute in running tap water and fixed for 5 minutes. If the target protein, MR 
or GR, was present, the film had a black band from the luminescence of the 
peroxidase on the secondary antibody.
Bradford Protein Analysis
A standard curve of pure protein concentration was created with bovine 
serum albumin (BSA). First, 25 mg BSA were mixed in 10 ml of TRIS buffer, 
which is a concentration of 2.5 mg/ml. 0.1 ml of the standard of 0.25 mg/ml was 
pipetted into two of the tubes containing 0.9 ml buffer and vortexed. 0.5 ml of
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the contents of these two tubes was transferred into the two tubes with 0.5 ml 
buffer and this dilution was repeated successively with the remaining tubes 
giving rise to 2 sets of tubes with 6 different concentrations of BSA. Aliquots of 
0.1 ml from each of the serial dilutions were pipetted into 2 sets of 6 tubes. 
Next, 0.7 ml buffer were pipetted in each of the appropriately labeled polystyrene 
tubes, followed by 0.2 ml of Bradford Reagent and vortexing each of the 
respective dilutions of 0.78, 1.56, 3.12, 6.25, 12.5, and 25 pg/ml.^^ Three blank 
tubes were made with 0.8 ml buffer + 0.2 ml Reagent.
A spectrometer was set at wavelength of 595 nm and zeroed with distilled 
water. The absorbance of the blank tubes was read versus the distilled water 
and then the fluid of the blanks was combined together. The combined blank 
fluid was placed in the reference beam cuvette and the absorbance of each of 
the samples containing tissue was found. The absorbance was compared to 
previous experiments using BSA.
A standard curve was then made for the tissue sample to find how the 
slope of absorbance of a tissue sample versus the of concentration of the tissue 
compared to the BSA protein analysis slope. This comparison provided an 
estimation of protein concentration in the sample. Twelve labeled tubes were 
used, the first three contained 0.8 ml TRIS buffer, the next three tubes contained 
800 pi buffer + Ip l homogenized tissue, the next three tubes, 800 pi buffer + 2 pi 
tissue and the final tubes, 800 ml buffer + 4pl tissue. The rest of the procedure 
was identical to that described above. (See Figure 11, page 49)
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Statisticai Analysis:
Between-within split plot analysis of variance and multiple comparison 
procedure in a Bonfronni recognition procedure were computed with SPSS 
software available available through the University of Montana mainframe 
com puter.D unnett's  test for comparison to a control baseline were computed 
with Minitab software also available through the mainframe.^^ The p<0.05 
was used as a minimum criterion of significance in all experiments.
Montana MedicAid Population Survey:
Montana MedicAid is a state program to help low income Montanas pay 
for medical bills. The supervising officers, Mr. Jeff Ireland and Ms. Dorothy 
Paulson, provided the 1995 anonymous data with a software package.
Chapter 3 
Results
24~Hour Activity:
On each test day, at least one rat from each treatment group was represented. 
Prior to treatment and after three days of intracerebral Alzet mini-pumps, the 
total 24-hour activity (indicated by total cage switch closures) of each animal 
was recorded. To remove the error associated with cage differences, each 
treatment activity was subtracted from baseline cage activity (average of all pre­
treatment recordings of the cage apparatus that measured the treatment rat's 
activity). The rats receiving spironolactone displayed a significant decrease in 
total 24-hour activity. Rats receiving aldosterone or vehicle did not show any 
significant difference in total 24-hour activity from baseline cage activity, and 
were not significantly different from each other. Rats are nocturnal animals, and 
the difference in cage activity was noticed primarily during dark (active) hours 
(See Figure 1 and Table 1). There was very little cage activity by the rats in any 
treatment group during the “lights on” period (See Figure 2 & Table 2). The 
ability of spironolactone to decrease activity supports the hypothesis that brain 
MR are involved, at least in part, for behaviors indicative of depression. That 
continuous agonist treatment did not alter activity may not be surprising as more 
than 80% of brain MR are thought to be bound even in the absence of the 
exogenous agonist treatment. 34
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Figure 1: Total 24-hour activity: Treatment minus Baseline of Cage 
Apparatus. Height of each bar represents the mean total activity per time period 
for all rats within each treatment group with baseline cage activity subtracted, 
and the vertical lines represent the SEM obtained from n=6 animals per group. *, 
significantly different p<0.05.
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Table 1: Analysis o f Variance 24-hour activity: Treatment minus Baseline of 
Cage Apparatus. Split plot analysis of variance examined difference in activity 
over time, activity of treatments for the sum of all the times, as well as an 
interaction of activity of treatments and time. There is a significant difference in 
activity depending on the time of day and total activity for 24-hours between the 
treatment groups.
Source DF S3 MS F P
Treatment Groups 2 11901 5950 8.94 0.003
Rats Nested Within Groups 15 9985 666
Hours 23 15793 687 1.99 0.005
Treatment Groups X Hrs 46 27427 596 1.72 0.004
Rats Nested Within Groups X Hrs 345 119308 346
Total 431 1184415
Hourly Activity: Tx minus PreTx Cage Error
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Figure 2: Hourly Activity: Net change in activity measured as the difference
between pre-treatment and treatment cage movements at hourly intervals over a
24-hour day in n=G animals per group. Lights are on from 7:00 to 19:00 hour.
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Table 2: Analysis of Variance Hourly Activity; Treatment minus Baseline of 
Cage Apparatus. Multiple comparison procedure examined differences between 
treatment groups at each time in a Bonfonni correction procedure nested on a 
pooled error term which is rats within treatment groups. #, significance p<0.05.
DARK Hrs 8PM 9 10 11 12AM 1 2 3 4 5 6 7
Spir X Aldo # # # - .  # .....................................................
SpirXVeh # # - - #
Aldo X Veh - - - - ^ - - - - ^ -
LIGHT Hrs 8AM 9 10 11 12PM 1 2 3 4 5 6 7
Spir X Aldo - - .....................................................
SpirXVeh -.................................................................................................................
Aldo X Veh - ...........................................................
Open Field Test:
Open field behavior was measured by counting squares entered (inner, 
outer and total) by each animal in a 10 minute period. Time of initiation of 
movement out of primary squares was also observed. All of the treatment 
groups demonstrated a decrease in the total, inner and outer squares entered 
compared to pre-treatment values, implying icv surgery and recovery caused 
anxiety in animals. The treatment groups did not significantly differ from each 
other in the total, inner or outer squares entered.(See Figure 3, 4 and 5, and 
Table 2) These open field tests were conducted in the morning when no 
difference in 24-hour activity levels were observed in the cage activity between 
the treatment groups. It is not known whether analysis of open field behavior in 
dark (active) period would have provided different results.
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Open Field Test: Total Squares Entered
I
%
PRE VEHICLE ALDO SPIRO
Figure 3: Open Field Test Total Squares Entered. Height of each bar 
represents the mean total squares entered for all rats within each treatment 
group (ALDO=aldosterone, SPIRO=spironolactone, SHAM=vehicle) and prior to 
treatment (PRE). The vertical lines represent the SEM. N=6 animals per 
treatment group, n=18 PRE animals. *, significantly different p<0.05 from PRE.
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Open Field Test; Outer Squares Entered
PRE VEHICLE ALDO SPIRO
Figure 4: Open Field Test Outer Squares Entered. Height of each bar 
represents the mean outer squares entered for all rats within each treatment 
group (ALDO=aldosterone, SPIRO=spironolactone, SHAM=vehicle) and prior to 
treatment (PRE). The vertical lines represent the SEM. n=6 animals per 
treatment group, n=18 PRE animals, *, p<0.05 , significantly different from PRE.
Open Field Test: Inner Squares Entered
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e 60
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PRE VEHICLE ALDO SPIRO
Figure 5: Open Field Test Inner Squares Entered. Height of each bar 
represents the mean Inner squares entered for all rats within each treatment 
group (ALDO=aldosterone, SPIRO=spironolactone) and prior to treatment 
(PRE)The vertical lines represent the SEM, n=6 animals per treatment group, 
n=18 PRE animals.
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Table 3: Open Field Test (a) Inner Squares (b) Open Squares and (c) Total 
Squares. Dunnett's test for comparison to a control baseline for an approximate 
analysis between baseline (PRE) and treatment rats was examined. It is 
approximate because PRE rats are distributed 6 at a time into treatment groups 
(but a conservative approximation because error was larger than it would be in 
the fully appropriate analysis). Total and outer squares entered by PRE were 
significantly different from treatment.
(a)lnner Squares Source DF SS MS F p
Treatment Groups 3 9877 3292 2.38 0.088
Animals Nested Within Groups 32 44278 1384
Total 35 54155
(b)Total Squares Source DF SS MS F p
Treatment Groups 3 1619684 539895 11.38 0.000
Animals Nested Within Groups 32 1518591 47456
Hours 35 3138274
Plasma Corticosterone Levels:
Plasma CORT levels demonstrated no differences between treatment 
groups at any time point examined. The mean of the first bleed (9AM, PRE) of 
plasma CORT was significantly higher than of the other plasma samples. (Table 
5) This may have indicated that basal levels of CORT had not been reached by 
the time of the first sampling from the change in environment. However, the 
levels fluctuated greatly between bleed times for an individual rat and between 
rats bled at the same time within the same group. The mean of minimal CORT 
value was in the range of 50-100 pg/ml, which also indicates a stress effect. The
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level of CORT was elevated in rats even at times expected to show a nadir in 
CORT secretion (Figure 6 and Table 4 & 5). These results imply that plasma 
CORT levels were somewhat elevated at all times examined and in all treatment 
groups. This effect was seen even considering that handling was minimized 
during the experiment. The fact animals had blood drawn in a room other than 
their usual housing and animals had less than one day to recover from the intra- 
jugular venous cannulatron surgery may have contributed to elevated CORT 
levels observed, although previous experiments using this technique have 
demonstrated a minimal effect of this minor surgery the previous day. °̂^
The lack of any difference of plasma CORT between any of the treatment 
groups was unexpected as acute studies have demonstrated changes in plasma 
CORT following acute administration of an icv MR agonist or MR antagonist. 
However, another chronic study manipulating brain MR with continuous infusion 
of MR antisense demonstrated no effect on CORT.
It was very difficult to obtain a plasma sample during the nocturnal hours 
from rats under red light because of the high activity of the rats at this time and 
the difficulty in seeing the blood. When obtained, often some manipulation of 
the animals had to be performed introducing a potential for stress. The ability to 
remove stress free dark hours blood samples would have been beneficial, since 
CORT plasma levels fluctuate in a circadian rhythm with higher levels occurring 
during dark hours, and the theory being tested in this research was that MR are 
involved in the regulation of this circadian rhythm of CORT.
Plasma Corticosterone
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□  Vehicle(G) 
BAIdosterone(6)
D Spironolactone(6)
o) 200
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9AM 2PM 6PM MIN
Figure 6: Plasma Corticosterone Levels at 9:00 (9AM), 14:00 (2PM),18:00 
(6PM), and the lowest sample (MIN). Height of each bar represents the mean 
plasma CORT [pg/ml] for all rats within each treatment group and prior to 
treatment (PRE) at 9:00, 14:00 and 18:00 hours; and the lowest value 
obtained/animal (MIN). The vertical lines represent the SEM. N=6 animals per 
treatment group, n=12 PRE animals. *, significantly different p<0.05.
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Table 4; Analysis o f Variance Corticosterone Levels o f Treatment and Pre- 
Treatm ent Animals. A Dunnett's test for comparison to a control baseline (pre­
treatment) was calculated for an approximate analysis between baseline and 
treatment animals for each time point and minimum corticosterone sample. It is 
approximate because the rats in baseline are distributed 6 at a time into the 
treatment groups and the not all the treatment animals matched up with a pre­
treatment measure (n=12) (but it is a conservative approximation because error 
was larger than it would be in the fully appropriate analysis). There was 
significantly higher CORT at 9AM of PRE versus treatment groups at 9AM.
MIN Plasma CORT, PreTx & Tx DF SS MS F P
Treatment and Pre Tx Groups 3 29074 9691 2.20 0.115
Animals Nested Within Groups 23 101212 4401
Hours 26 130286
9AM CORT, PreTx & Tx DF SS MS F P
Treatment and Pre Tx Groups 3 89895 29965 3.39 0.035
Animals Nested Within Groups 23 203122 8831
Hours 26 293016
2PM Plasma CORT, PreTx & Tx DF SS MS F P
Treatment and Pre Tx Groups 3 20382 6794 0.31 0.818
Animals Nested Within Groups 23 505037 21958
Hours 26 525420
6PM Plasma CORT, PreTx & Tx DF SS MS F P
Treatment and Pre Tx Groups 3 52791 17597 2.14 0.123
Animals Nested Within Groups 23 189068 8220
Hours 26 241859
Table 5: Analysis o f Variance of Corticosterone Levels of Treatment 
Animals. Between-within split plot analysis of variance examined difference of 
plasma CORT between treatment groups over time of day, the main effects of
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treatment and time of day, as well as an interaction of treatment and time of day. 
There was no significant difference in plasma CORT depending on the time of 
day or plasma CORT between treatment groups by time of day or between total 
CORT of the treatment groups.
Plasma CORT Source DF SS MS F P
Treatment Groups 2 8568 4284 0.38 0.691
Rats Nested Within Groups 15 169425 11295
Time of Day 2 1658 829 0.09 0.912
Treatment Groups X Time of Day 4 9918 2480 0.28 0.891
Rats Nested Within Groups X Time 30 269176 8973
Total 53 458745
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Figure 7: Standard Curve of Plasma CORT for RIA.
The percentage of gamma counts per minute (cpm) for known quantities of 
CORT (B) are calculated from the absence of CORT (BO), cpm of non-specific 
binding of secondary antibody (NB) is subtracted from both B and BO. These 
are compared in a logit versus log graph against the ng quantity of CORT.
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Cannutae Patency:
Immediately, after animals were sacrificed, the cannulae were tested for 
patency and by six days the cannula of several animals were not patent. In 
studies performed after the experiment it was demonstrated that most cannulae 
would have remained patent for 3-4 days even with the vehicle and flow 
parameters used.
Western Biot of Kidney and Hippocampal MR and GR:
The positive binding of kidney MR and the lack of antibody binding in the 
hippocampus could be interpeted that the kidney and hippocampal MR are not 
identical proteins. The dénaturation of Western blots would remove ligands from 
protecting the MR antibody binding site. Several concentrations and 
purifications of MR and MR antibody yielded identical results. The positive GR 
antibody binding in both hippocampal and kidney, demonstrates GR presence in 
both hippocampal and renal tissues.
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Figure 8: MR and GR Western Blots of Kidney and Hippocampus.
a.)The black bands are from the chemoluminescence of MR monoclonal 
antibody binding of kidney tissues at 200|xg (positive control), 10pg, 50pg, 
100pg and 200pg total denatured protein/well (+C, K10, K50, K100, K200). To 
the left of each kidney sample an equal concentration of hippocampal tissue was 
placed, except for +C (H10, H50, H100, H200).
b,)The black bands are from the chemoluminescence of GR antibody binding of 
renal (K) and hippocampal (HI) tissues at 200pg total denatured protein/well.
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Immunocytochemistry (ICC) of Kidney and Hippocampal MR and GR:
The similarity of ICC results with Western blot results further strengthen 
the observation that the kidney and hippocampal MR appear to be unidentical 
proteins. However, hippocampal MR are thought to be substantially ligand 
bound, which could mask the MR antibody binding site.
S . ♦  V ^
a.)MR in kidney b.)GR in kidney
Figure 9: MR and GR ICC of Renal Tissue (20x Magnification).
a.) The stained cells are MR monoclonal antibody binding MR in kidney tissue.
b.) The stained cells demonstrate GR antibody binding in kidney.
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a.)MR in hippocampus b.)GR in hippocampus
Figure 10: MR and GR ICC of Hippocampal Tissue (20x Magnification).
a.) This figure shows a lack of MR antibody binding in hippocampal dentate 
gyrus tissue.
b.) The arrows in this figure point to stained cells in hippocampal dentate gyrus 
tissue binding GR.
1995 Survey of Montana Medic Aid Antidepressant Recipients:
50
There were three to four times more women recipients of antidepressants 
than men for any adult age group. Women in their child bearing years were by 
far the largest number of recipients of antidepressant drugs.
25%
20%
15%
10%
5%
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Percent Anttdepressant Recipients
Total
□  Female
□  Male
Total 0to20 21to64 65+
Figure 11: Percent o f 1996 Montana Medic Aid recipients receiving 
antidepressant drugs, categorized by gender and age. Height of each bar 
represents the percentage of total, male and female patients receiving 
antidepressant prescriptions in three age categories from the sample population 
of people eligible for Montana MedicAid. The data demonstrate expected 
differences in gender specific antidepressant therapy based on previous 
literature data demonstrating a higher percentage of women with clinically 
diagnosed depression than men. However, although literature predicts older 
patients will be clinically diagnosed with depression at a higher rate than 
younger individuals, the present results demonstrate that women and men in the
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21-64 age group show as high an Incidence of antidepressant prescriptions as 
the ages 65+.
Number of Antidepressant Recipients
B Female 
Male
"5. 1000
« 800
0
Age
Figure 12: Number of 1996 Montana MedicAid recipients receiving 
antidepressant drugs, categorized by gender and age. Height of each bar 
represents the number of total, male and female antidepressants recipients of 
Montana MedicAid further segregated by age.
This breakdown demonstrates that the largest number of people receiving 
antidepressant prescriptions In this survey population is associated with women 
in child-bearing years (21-40).
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Figure 13: Standard Curve of pure protein concentration created with BSA.
The lines are representative of the reading on a spectrometer at OD 595 
wavelength with various known amounts of BSA in a Bradford dye.
Chapter 4 
Discussion
Osmotic Pump Experiment
Chronic spironolactone reduced rat total 24-hour locomotor activity, most 
noticibly during the active hours, which for rats is during the dark phase (19:00- 
7:00 hours). This provides evidence that 1) MR are linked to locomotor activity 
and potentially to depression and 2) are important when CORT levels, and 
subsequently GR activation are believed to be highest. The manner by which 
this linkage is manifested was unexpected from the action of brain MR proposed 
in the literature.
Meijer and de Kloet proposed that a continuous decrease in limbic GR 
and a high ratio of activated MR to GR in the hippocampus are involved with 
depression by reducing brain serotonin, hippocampal serotonin’s 1A receptor (5- 
HTia), and attenuating 5-HTia neuronal hypopolarization.^°® The effect of stress 
to increase In the activity of the rate limiting enzyme of serotonin synthesis, 
tryptophan hydroxylase is blocked by central administration of a GR antagonist. 
107 108 109 activation and circulating CORT appear to both enhance
tryptophan hydroxylase expression and neuronal serotonin release (capacity).
111 112 Therefore, decrease in brain GR could decrease serotonin synaptic
release, which has been theorized to be associated with depression
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5-HTia agonists have many central effects and some 5-HTia agonists are 
used as antidepressants and anxiolytics, such as buspirone, ipsapirone and 
flesinoxan/^^ This G-protein coupled serotonin receptor, 5-HTia, is 
physiologically influenced by MR in at least two manners. MR activation 
decreases the protein expression of S-HTia .̂ "̂* In electrophysiological
experiments of hippocampal neurons which co-express MR, GR and 5-HTia, an 
MR agonist attenuates the neuronal response (hypopotarization) to serotonin 
and 8 -0 H DPAT (a specific 5-HTia a g o n i s t ) . T h e  MR agonist effect is 
removed by co-administration of a GR agonist. Therefore, serotonin’s effects on 
these 5-HTia receptors would be most influential during physiological states of 
high CORT and least influential at low CORT or low GR activation, but not 
complete CORT removal. Electrophysiological effects have been observed to be 
decreased with both short-term and long-term administration of low CORT to the 
hippocampal neurons.
In the Meijer and de Kloet model, low GR would result in a decrease in 
serotonin production by the raphe nuclei and dexamethasone would fail to 
suppress CORT by binding to hypothalamic GR. The high hippocampal MR/GR 
ratio would attenuate 5-HT ia hypopolarization of neurons and decrease 5-HT ia 
expression. These effects, they theorize, would contribute to depression.
The present results, that an MR antagonist decreases locomotor activity, 
do not contradict that low GR could be involved in depression, but they provide 
evidence that low MR might also be involved. Continuous administration of
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spironolactone into the brain would have been expected to decrease the MR to 
GR ratio, increasing 5-HT ia protein expression and hypopolarization effect. 
These predicted effects were thought not to induce depression-like behavior, 
such as low total 24-hour locomotor act iv i ty .However ,  spironolactone lowered 
activity during the dark (active) hours, when GR activation should be high and 
thus, high hippocampal GR/MR ratio. The neurochemical systems involved in 
this lowering of locomotor activity are unknown, but, hippocampal 5-HTia is an 
unlikely candidate. Although, 5-HTia has effects on locomotor activity most 
literature reviewed (from a Medline search of abstracts) implied this effect is from 
the 5-HTia in the suprachiasmatic nucleus and the raphe nuclei, while serotonin 
5-HTib receptors, catecholaminergic receptors and other receptors are involved 
in locomotor activity at the hippocampus.
The depression-like effects of both MR and GR provides for an alternative 
hypothesis to be proposed. Both the activated MR and the activated GR bind to 
the same sequences of DMA response elements (GRE) and to individual 
response elements, MRE and GRE. Activated hippocampal MR or GR are 
found co-localized in some nuclei compartments and not co-localized in other 
nuclear compar tments .The dimerization of steroid receptors is thought to be 
necessary for steroid/transcription interactions to occur. This dimerization 
occurs after one activated receptor has already bound to the proper GRE.^^  ̂
Both homodimers and heterodimers can occur with MR and GR respectively/^ 
It is quite feasible, that DNA response elements could exist for GR+GR, MR+MR
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and MR+GR dimers or that one receptor of the dimer could be replaced by 
another, making a homodimer into a heterodimer. In normal physiological 
conditions CORT binding GR fluctuates from 5% to 90% with the circadian level 
of available CORT, while almost all MR are thought to be bound and activated. 
In this condition, the binding and activation of GR would be the limiting factor for 
the MR+GR heterodimer. By pharmacologically lowering MR binding by 
interactions with spironolactone, the MR+GR heterodimer would also be 
decreased like it is in circumstances of low CORT and low GR activation, except 
now the availability of MR is the limiting factor. Therefore, the MR+GR 
heterodimer would be decreased by low MR or low GR. Perhaps, this MR+GR  
heterodimer is involved in clinical depression.
Another possible explanation might be that MR+MR homodimer alters the 
expression of a protein and this alteratrion of the protein would be necessary in 
order for GR+GR alterations of a separate protein(s) to occur. Therefore, either 
low MR or low GR activation would be involved in depression. Similar to what 
was observed in low activated brain MR In rats, adrenalectomized (ADX) rats 
(when neither MR nor GR are activated) demonstrated a decrease in total 24- 
hour wheel running activity, but no change in the circadian rhythm of activity.^^^
Explorative behavior of treatment animals (including vehicle) all 
decreased from before treatment values, but there was no difference between 
treatment groups. In addition, the animals did not appear sickly nor was there 
difference in body weight in any of the treatment groups (data not shown).
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Therefore, it is unlikely the differences in total 24-hour locomotor activity are 
from an effect other than spironolactone treatment.
If both MR and GR are necessary for GR to have effects on the 
serotonergic system, then the half of the hypothesis described by Meijer and de 
Kloet would be correct. Low GR activation results in low serotonin synthesis and 
release contributing to depression. However, there may need to be MR 
activation In order for GR to exert a definitively full effect on locomotor activity 
and on moods.
Activated dimer low or no MR+GR mid MR+GR high MR+GR
Serotonin low mid high
Locomotor Activity low or none mid high
CORT regulation poor average ?
Mood depressed/sleep mid manic
Table 6: Proposed relationship between activated MR+GR level, locomotor 
activity, serotonergic activity, CORT regulation and mood.
This change in activity and possibly serotonin levels, indicates that both 
the MR and GR might be involved in the etiology of depression. Animals 
receiving acute brain Injections of MR antagonists exhibit "depression-like”
behaviors. 128 129 130 Activated hippocampal MR directly and independent of GR
suppress 5-HT ia expression. 118 131 A high number of 5-HT ia (Implying low MR)
are seen in patients who suffer from depressive disorders and in people who
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have committed suicide by non-violent means/^^ These high levels of 5 -H T ia  
could have resulted from low MR (hippocampal 5 -H T ia ). Brain MR are thought 
to be involved in the regulation of plasma CORT. ^  Low brain MR would 
cause a lack of CORT regulation in a similar manner to that seen in depression. 
Antidepressants cause an increase in hippocampal MR in a time course similar 
to their therapeutic effects. es ee e? es es 70 Q R  and MR are reduced with 
chronic immobilization (learned helplessness) and similar chronic stresses, while 
5 -H T ia  receptors increase. Thus, low brain MR activation may well be
involved in the etiology of certain types of depression.
However, only one patient case has been reported of spironolactone 
being associated with depression.^^ Of note, lethargy (decreased locomotor 
activity) is a side effect of spironolactone diuretic therapy . In te res t in g ly ,  
spironolactone has been successful as a substitute of lithium in bipolar disorder 
p a t i e n t s . H o w e v e r ,  the pharmacological dose administered directly into the 
brain to rats in this experiment were at a much greater concentration in the brain 
than a pharmacotherapeutic dose administered orally to people. This might 
explain, the lack of complaints of depression in people taking spironolactone. 
Another explanation is that MR antagonists do produce lethargy, but not lethargy 
associated with depression.
That the MR agonist, aldosterone, did not alter locomotor activity at all, is 
not a surprise, because a high percentage of MR are always bound, so adding
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an exogenous ligand to an already at least 80% activated receptor might have 
little net effect.
Hippocampal MR were predicted to be involved with regulation of CORT 
levels, for it had been shown that acute administration of MR agonists decreased 
CORT and MR antagonists Increased CORT.^® ^  However, in the present 
study there was no change in plasma CORT between any treatment groups. 
The effects of the drug treatments could have been masked by stress of being in 
a new environment, resulting in high CORT levels. However, several 
precautions were taken to minimize this possibility. Animals were brought up in 
their home cages several hours before the experimentation. Cannula were 
connected to collecting tubes at least one hour prior to removal of the first blood 
sample, and many precautions were taken to assure stable, quiet lab conditions 
during the course of the experiments. Another possibility is that the brain 
adjusted to the chronic drug treatments and thereby normalized CORT levels. A 
similar chronic study of manipulating brain MR by continuous infusion of MR 
antisense (MRAS) also had no effect on CORT levels.®^
The ability to remove stress free blood samples during dark hours would 
have been beneficial, since CORT plasma levels fluctuate in a circadian rhythm 
with higher levels occurring during dark hours. This is especially true since, 
spironolactone effects on locomotor activity were noticeable only during the dark 
hours. However, it was very difficult to obtain a plasma sample during the 
nocturnal hours from rats under red light. When obtained, often some
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manipulation of the animals had to be performed introducing a potential for 
stress and altered CORT levels.
In the future, a study should be conducted on CORT levels after a 
dexamethasone bolus to see if CORT regulation is altered by the low activated 
MR In the brain.
1995 Survey of Montana MedicAid Antidepressant Recipients
The 1995 survey of Montana MedicAid patients showed at least three 
times more women received anti-depressant therapy versus men and that 
women in their child bearing years represented by far the largest antidepressant 
prescription recipients. The higher incidence of women diagnosed with 
depression compared to men has been previously reported and might be 
influenced by estrogen and/or progesterone levels. A large change in plasma 
estrogen or progesterone concentrations has been associated with clinical 
depression; Including the dramatic decrease which occurs in estrogen and 
progesterone after child birth or menopause, or the increase in estrogen and 
progesterone which can result from drug contraceptive therapy.®  ̂® It is possible 
that the highest frequency of recipients of an antidepressant prescription 
(women between the ages 21-40) corresponds also with the highest use of drug 
contraceptives. The analysis utilized could not show recipients of concurrent 
prescriptions, such as oral contraceptives and antidepressants, which would 
have been interesting considering the highest number of prescriptions for drug
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contraceptives occur In the age group of the highest number of antidepressant 
prescriptions.
Interactions between gonadal hormones and CORT and CORT receptors 
do o c c u r . F e m a l e s  (both human and animal) are known to have 
higher basal CORT, as well as larger responses to stress and immune 
challenges than males/'*^ The level of CORT and CORT sensitivity to
various stressors fluctuates with the menstrual cycle.̂ "*® Progesterone is a very 
strong MR antagonist in vitro, with a higher affinity than spironolactone and in 
vivo (but estrogen appears to need to be present for this effect, implying 
progesterone in vivo effects on MR may not be directly at the MR binding 
domain).^^^ Either spironolactone or progesterone have been successful 
prophylactic therapeutics of pre-menstrual syndrome (RMS), this suggests that 
hippocampal MR activation or MR+GR activation might be too high in RMS.
One should keep in mind that the survey includes primarily people with 
low income. Certainly, some of the women in child bearing years are single 
mothers. Since a large percentage of these women are probably receiving birth 
control, perhaps the oral contraceptives are a factor In the depression. Another 
possibility is that antidepressant drugs are the latest "Mother's Littie Helper*', a 
Brave New World soma, which removes emotions to help mothers with the 
stress of raising children. In this sense, the antidepressants may also be 
overprescribed in these age groups. This brings up some serious social Issues 
about Montana, if many of our mothers are on antidepressants.
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Monoclonal MR Antibody Specific to the Ligand-Binding Site Experiment
The monoclonal antibody specifically raised to the ligand-binding site of 
the peripheral MR in the kidney, did not bind to hippocampal MR in the present 
study, either by western blot or immunocytochemistry (ICC) analysis. The ICC 
detection of hippocampal MR could have been potentially masked by the ligand, 
because most MR are thought to be ligand bound. However, the tissue samples 
in the western blot analysis were boiled for two to three minutes, incubated with 
a powerful detergent and moved through a gel by a high power electrical circuit. 
By definition and from these conditions, all the proteins in a western blot are 
thought to be denatured. It is unlikely, that such a denatured protein would still 
be masked by a ligand. In order, to make sure that the lack of MR binding was 
not from low protein concentration, up to 300 pg total protein of a tissue sample 
had been placed in a well. The hippocampal tissue GR was detected in an 
identical procedure, using a polyclonal antibody to GR. Currently, no such 
polyclonal antibody commercially exists for brain MR analysis.
Therefore, the most likely conclusion from the present MR results is that 
ligand binding site of MR in the hippocampus is not the same amino acid 
composition as the ligand binding site of MR in the kidney. The difference in the 
ligand-binding domain of MR could represent a difference in active versus 
inactive MR, or it could truly represent a difference in hippocampal versus 
kidney MR. Splice variants of MR have been found in the hippocampus.^^®
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Certain fragments of activated, but not inactivated MR are resistant to 
proteolysis/^^ This indicates that a structural change occurs in MR upon 
ligand activation. Earlier studies have suggested that there is a slight variation 
between the hippocampal and kidney MR, which might allow for the ligand 
specificity of the t i s s u e s . N o n - p e p t i d e  post-translational modifications 
could also explain the various observed difference between kidney and 
hippocampal MR, such as sugar or lipid additions or deletions.
In the future, a study should be conducted on the binding of the 
monoclonal antibody in chronically adenalectomized rats. This would allow the 
hippocampal MR to assume an unbound inactive form. If there still is no binding 
by the monoclonal antibody to these MR, then the only remaining possibility is 
that brain MR are distinct from peripheral MR.
Since, spironolactone has been successfully used in the treatment of bi­
polar disorder and pre-menstrual syndrome and that lithium has MR antagonist­
like qualities, then high MR+MR homodimer or high MR+GR heterodimer or 
both, might be involved with manic-like moods. The low brain GR theory of 
depression, coupled with the decrease of locomotor activity in these experiments 
suggest that low MR+GR heterodimer might be involved in depression. Novel 
drugs which enhance activated MR+GR in a time course faster than present 
therapeutics may represent future antidepressants. The lack of a monoclonal 
antibody bound to the ligand binding site of hippocampal tissue, but functional 
binding to MR In renal tissue, suggests the ligand-binding site might be different.
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Since, spironolactone has successfully been used as a mood stabilizer, perhaps 
to high MR+GR are involved with bi-polar disorder. Future mood stabilizers 
might make use of the binding-site difference to specifically block brain MR.
Summary
1. The chronic brain administration of a MR antagonist lowered total 24-hour 
locomotor activity suggesting that the brain MR may be involved in the etiology 
of behaviors associated with depression.
2. A survey of people eligible for Montana MedicAid in 1995 found three times 
more women received antidepressants than men and the largest group of 
recipients was women between the ages 20 to 40 years. Whether this was 
correlated to oral contraceptives or other gonadal hormone factors was not 
discernible in the present analysis.
3. Hippocampal MR were not detectable with a monoclonal antibody specific to 
the peripheral ligand binding site, while kidney MR were detected. This was true 
for both western blot and ICC analysis. The data suggest that two different MR 
proteins exist, either from post-activation alterations or pre-activation 
expression/ alteration.
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